Find in Library

Introduction. Glioblastoma multiforme is one of the most aggressive primary brain tumor, with a poor prognosis. Aim. This study assesses the outcomes of patients with newly diagnosed glioblastoma treated in our hospital with multimodal treatment consisting of surgical resection, concurrent chemoradiotherapy with Temozolomide and adjuvant six cycles Temozolomide, depending on clinical prognostic factors. Materials and methods. Clinical data from 47 glioblastoma patients treated in OncoFort Hospital from January 2015 to December 2017 were analyzed. The following data were extracted from medical records of the patients: age, gender, Karnofsky Performance Status, tumor location, size of tumor, type of surgery, postoperative treatment and survival time between diagnosis and time of last contact. Results. Our statistical analysis showed a longer survival among patients with of Karnofsky Performance Scale ≥80, tumor dimension<4 cm, gross-total resection and extended chemotherapy with Temozolomide for more than 6 cycles. Conclusions. GBM remains an incurable disease. The multidisciplinary approach is recommended to optimize results for this malady